Tenarad is is the radiolabeled version of the human vascular targeting antibody F16, specific to the A1 domain of tenascin-C, expressed in a recombinant format which has been proven to display better tumor selectivity in vivo compared to the conventional IgG format.

This product has recently entered multicenter clinical trials for the therapy of a broad range of solid and hematological tumor  malignancies. The study design foresees the screening of patients with scintigraphic techniques, followed by radioimmunotherapy in those patients which display a tumor radiation dose at least ten times greater than the dose delivered to the bone marrow.

Similar to L19-131I, Tenarad represents a non-painful therapeutic option for patients, which may become preferable to conventional chemotherapy and external beam radiation.

SELECTED REFERENCES
Berndt et al. (2010) Histochem Cell Biol, 133, 467-475;
Pedretti et al. (2008) Lung Cancer, 118, 1805-1813;
Brack et al. (2006) Clin. Cancer Res., 12, 3200-3208;
Silacci et al. (2006) PEDS, 19, 471-478;

<< Pipeline